Exelon

← The FDA Ephemeris: the whole map

Exelon rivastigmine tartrate

Listed: the approval is known from Drugs@FDA; its review documents are not yet in the Ephemeris.

Application: NDA 20823 · NDA 21025 · NDA 22083
Sponsor: Novartis
Drug class: Cholinesterase inhibitor
First approved: April 21, 2000
Drugs@FDA status: Discontinued · Prescription

NDA 20823 on Drugs@FDA · NDA 21025 on Drugs@FDA · NDA 22083 on Drugs@FDA

Also cholinesterase inhibitors: Cognex, Aricept, Razadyne, Aricept ODT, Razadyne ER, Adlarity, Zunveyl

From FDA documents. Not medical advice.

Anti-amyloid antibody

Aduhelm aducanumab-avwa
Leqembi lecanemab-irmb
Kisunla donanemab-azbt
Leqembi Iqlik lecanemab-irmb, subcutaneous

Regulatory records

Cholinesterase inhibitor

Cognex tacrine hydrochloride
Aricept donepezil hydrochloride
Exelon rivastigmine tartrate
Razadyne galantamine hydrobromide
Aricept ODT donepezil hydrochloride
Razadyne ER galantamine hydrobromide
Adlarity donepezil hydrochloride
Zunveyl benzgalantamine gluconate

NMDA receptor antagonist

Namenda memantine hydrochloride
Namenda XR memantine hydrochloride

Amyloid PET imaging agent

Amyvid florbetapir f-18
Vizamyl flutemetamol f-18
Neuraceq florbetaben f-18

Combination

Namzaric donepezil hydrochloride; memantine hydrochloride

Atypical antipsychotic

Rexulti brexpiprazole

Tau PET imaging agent

Tauvid flortaucipir f-18

Group by

Build queue · replay at pipeline speed